cabazitaxel / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

20 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cabazitaxel / Generic mfg.
2011-004712-32: A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.

Not yet recruiting
2
31
Europe
CABAZITAXEL, Concentrate and solvent for solution for infusion, JEVTANA
UNICANCER, Sanofi Aventis
Recurrent or metastatic head and neck cancer, Diseases [C] - Cancer [C04]
 
 
2015-004937-29: Cabazitaxel response prediction by FCH-PET.

Ongoing
2
30
Europe
[18F]-Fluorocholine, Radiopharmaceutical precursor
VU University Medical Center, Sanofi-Aventis The Netherlands, Cyclotron BV
Metastatic castration-resistant prostate cancer., Metastatic hormone-insensitive prostate cancer., Diseases [C] - Cancer [C04]
 
 
2016-004963-38: Optimal patients with Metastasized Hormone Resistant Prostate Cancer Previously Treated with Docetaxel Optimale behandeling voor patienten met een uitgezaaide hormoonongevoelige prostaatkanker die eerder zijn behandeld met docetaxel.

Ongoing
2
152
Europe
Cabazitaxel/ Jevtana, Xtandi (enzalutamide), Zytiga (abiraterone acetate), XRP6258, Concentrate and solvent for concentrate for solution for infusion, Capsule, soft, Tablet, Jevtana (cabazitaxel), Xtandi (enzalutamide) 40mg soft capsules, Zytiga
Netherlands Cancer Institute, Sanofi Genzyme
Metastasized Castration Resistant Prostate Cancer Gemetastaseerd Castratieresistent Prostaat carcinoom, Prostate cancer Prostaatkanker, Diseases [C] - Cancer [C04]
 
 
Bristol Bladder, NCT01616875 / 2011-004090-82: Trial

Active, not recruiting
2
28
Europe
Cabazitaxel + Cisplatin chemotherapy, Jevtana
University Hospitals Bristol and Weston NHS Foundation Trust, Sanofi
Infiltrating Bladder Urothelial Carcinoma
11/17
01/23
2017-001591-35: Multicenter, prospective, non-randomized, phase II trial designed to evaluate the activity of Cabazitaxel in patients with advanced Adreno-Cortical- Studio multicentrico, prospettico, non randomizzato, di fase II volto a valutare l’attività di Cabazitaxel in pazienti affetti da carcinoma corticosurrenale avanzato in progressione dopo precedenti linee di chemioterapia citotossica

Ongoing
2
25
Europe
JEVTANA, [cabazitaxel], Solution for infusion, JEVTANA - 60MG-CONCENT. E SOLV.PER SOLUZ. PER INFUSIONE-USO ENDOVENOSO -CONCENT.:FLACONC.(VETRO)SOLV.: FLACONC.(VETRO)-CONCENT.:1.5ML SOLV.:4.5ML-1FLAC.+1FLAC.
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, AIRC, SANOFI -fornitura gratuita farmaco
Histologically confirmed diagnosis of ACCLocally advanced or metastatic disease not amenable to radical surgery resection Diagnosi istologica di carcinona cortico-surrenale (ACC) Malattia localmente avanzata o metastatica non suscettibile di resezione chirurgica radicale, diagnosis of ACC carcinona cortico-surrenale, Diseases [C] - Cancer [C04]
 
 
2016-001253-41: Impact of cabazitaxel on metastatic bone disease in prostate cancer Impatto di cabazitaxel sulle metastasi ossee in pazienti affetti da cancro della prostata

Ongoing
2
107
Europe
CABAZITAXEL, [IMP1], Powder for solution for infusion, JEVTANA - 60MG-CONCENT. E SOLV.PER SOLUZ. PER INFUSIONE-USO ENDOVENOSO -CONCENT.:FLACONC.(VETRO)SOLV.: FLACONC.(VETRO)-CONCENT.:1.5ML SOLV.:4.5ML-1FLAC.+1FLAC.
GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE, Sanofi S.p.a
1. Histologically or cytologically confirmed adenocarcinoma of prostate that is resistant to hormone therapy and previously treated with a docetaxel containing regimen. Adenocarcinoma prostatico confermato istologicamente o citologicamente resistente alla ormonoterapia e trattato precedentemente con una terapia contenente docetaxel., Prostate cancer that is resistant to hormone therapy and previously treated with a docetaxel containing regimen. Tumore della prostata non rispondente a ormonoterapia e trattato precedentemente con una terapia contenente docetaxel, Diseases [C] - Cancer [C04]
 
 
CABA-V7, NCT03050866: Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

Active, not recruiting
2
140
Europe
Cabazitaxel, Jevtana, Antihistamine, Corticosteroid, H2 antagonist, histamine H2 receptors blockers, Antiemetic
Erasmus Medical Center, Sanofi
Circulating Tumor Cell, Metastatic Prostate Cancer
01/22
08/22
CheckMate 650, NCT02985957 / 2016-001928-54: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

Checkmark From CheckMate-650 trial in combination with Yervoy for 2L mCRPC
Sep 2020 - Sep 2020: From CheckMate-650 trial in combination with Yervoy for 2L mCRPC
Checkmark In combination with Yervoy (CheckMate 650 trial)
Mar 2019 - Mar 2019: In combination with Yervoy (CheckMate 650 trial)
Active, not recruiting
2
351
Europe, Canada, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Cabazitaxel, Prednisone
Bristol-Myers Squibb
Prostate Cancer
04/22
01/25
2020-000209-10: Phase II two-arm study of AZD4635 in combination with durvalumab and in combination with cabazitaxel and durvalumab in patients with mCRPC

Not yet recruiting
2
160
Europe
Durvalumab, Cabazitaxel, AZD4635, MEDI4736, Capsule, hard, Concentrate for solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Jevtana
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Progressive Metastatic Castrate-Resistant Prostate Cancer, Prostate Cancer, Diseases [C] - Cancer [C04]
 
 
NCT02478502 / 2012-004418-32: Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Terminated
2
14
Europe
cabazitaxel, Jevtana
University Hospital, Akershus, Sanofi
Testicular Cancer
12/22
12/22
2022-003792-41: Chemotherapy with or without darolutamide in men with metastatic prostate cancer.

Not yet recruiting
2
245
Europe
Nubeqa, Tablet, Nubeqa/Darolutamide
Erasmus MC, Bayer
metastatic castration-resistant prostate cancer, Prostate cancer spread to other parts of the body, Diseases [C] - Cancer [C04]
 
 
NCT05005728: XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
85
US
vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
Xencor, Inc.
Metastatic Castration-Resistant Prostate Cancer
03/25
09/25
NCT02218606: Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Completed
2
80
US
Abiraterone acetate 1000 mg po daily, Cabazitaxel 25 mg/m2 IV, prednisone 5 mg po BID
Memorial Sloan Kettering Cancer Center, Sanofi, Thomas Jefferson University, Weill Medical College of Cornell University
Prostate Cancer
10/23
10/23
NCI-2018-01071, NCT03263650: Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Active, not recruiting
2
119
US
Cabazitaxel, Jevtana, Carboplatin, Paraplatin, Prednisone 5Mg, Olaparib, Olaparib Pill
M.D. Anderson Cancer Center, AstraZeneca, Merck Sharp & Dohme LLC
Prostate Cancer Aggressiveness, Prostate Carcinoma
06/24
06/24
CABPOSTAAT, NCT03764540: Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide

Active, not recruiting
2
214
Canada
Cabazitaxel plus prednisone, Experimental, Docetaxel plus prednisone, Active Comparator
Centre hospitalier de l'Université de Montréal (CHUM), Genzyme, a Sanofi Company
Metastatic Prostate Cancer
07/24
09/24
CHAMP, NCT04709276: A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Recruiting
2
43
US
Nivolumab, BMS-936558, MDX1106, ONO-4538, Ipilimumab, BMS-734016, MDX010, MDX-CTLA4, Carboplatin, Cabazitaxel, JEVTANA
Andrew J. Armstrong, MD, Bristol-Myers Squibb
Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
12/24
06/27
NCT04592237: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting
2
120
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetrelimab, JNJ 63723283, JNJ-63723283, JNJ63723283, WHO 10757, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, Janssen Pharmaceutica
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
12/25
12/25
2006-003085-34: A Dose-escalating, Multicenter, Single arm, Open-label Study of XRP6258 in combination with capecitabine (Xeloda®), in patients with metastatic breast cancer with disease progressing after anthracycline and taxane therapy

Ongoing
1/2
50
Europe
XRP6258, Concentrate for solution for infusion, Film-coated tablet, Xeloda
sanofi-aventis recherche & developpement
Metastatic Breast Cancer
 
 
NCT02202772: Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Active, not recruiting
1/2
51
US
Cabazitaxel, Jevtana, Gemcitabine, Gemzar, Cisplatin, Platinol, Platinol-AQ
Guarionex J. Decastro, Sanofi
Urothelial Carcinoma of the Urinary Bladder
04/26
04/28
MK-5684-01A, NCT06353386: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Recruiting
1/2
220
RoW
Opevesostat, MK-5684, Olaparib, LYNPARZA®, Docetaxel, TAXOTERE®, Cabazitaxel, JEVTANA®, Fludrocortisone acetate, Dexamethasone, Prednisone
Merck Sharp & Dohme LLC, Orion Corporation, Orion Pharma
Prostatic Neoplasms, Castration-Resistant
03/28
03/28

Download Options